Literature DB >> 9306898

Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.

D J White1, C Billingham, S Chapman, S Drake, D Jayaweera, S Jones, A Opaneye, C Temple.   

Abstract

OBJECTIVE: To compare the effectiveness and cost of self treatment of penile warts with a commercial preparation of podophyllotoxin 0.5% (PDX 0.5%) with podophyllin 0.5% and podophyllin 2.0% sourced from Podophyllum emodii.
DESIGN: A prospective double blind randomised study.
SUBJECTS: 315 patients with penile warts attending two departments of genitourinary medicine. MAIN OUTCOME MEASURES: Absence of warts, cessation of treatment due to severe side effects at 5 weeks.
RESULTS: Of the 315 patients, 244 conformed to the protocol. Analysis was on an intention to treat basis. At 5 weeks no significant differences were found in the extent of healing of warts or in side effects for the three treatment groups. The costs of drug treatment (excluding staff time) are at least pounds 10.00 less for podophyllin than podophyllotoxin. A fourfold variation in the active constituents of the podophyllin preparations did not produce appreciably different clinical responses. In a subanalysis no evidence of deterioration in effectiveness of podophyllin over time was demonstrated.
CONCLUSIONS: Penile warts in selected cases can be safely treated with 0.5-2.0% podophyllin self applied by the patient at a fraction of the cost of commercially available podophyllotoxin. The shelf life of the podophyllin extracts is at least 3 months. These findings may be especially relevant in countries where resources for health care are limited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9306898      PMCID: PMC1195818          DOI: 10.1136/sti.73.3.184

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  5 in total

1.  The cost effectiveness of treatment of genital warts with podophyllotoxin.

Authors:  K C Mohanty
Journal:  Int J STD AIDS       Date:  1994 Jul-Aug       Impact factor: 1.359

2.  Self-treatment of condylomata acuminata with podophyllin resin.

Authors:  H Maiti; K R Haye
Journal:  Practitioner       Date:  1985-01

3.  An open, comparative, study of the efficacy of 0.5% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females.

Authors:  G R Kinghorn; A McMillan; F Mulcahy; S Drake; C Lacey; J S Bingham
Journal:  Int J STD AIDS       Date:  1993 Jul-Aug       Impact factor: 1.359

4.  Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts.

Authors:  A Edwards; A Atma-Ram; R N Thin
Journal:  Genitourin Med       Date:  1988-08

5.  Quercetin and kaempherol: an argument against the use of podophyllin?

Authors:  C S Petersen; K Weismann
Journal:  Genitourin Med       Date:  1995-04
  5 in total
  6 in total

Review 1.  Warts (genital).

Authors:  Henry W Buck
Journal:  BMJ Clin Evid       Date:  2010-08-13

Review 2.  Warts (genital).

Authors:  Henry W Buck
Journal:  BMJ Clin Evid       Date:  2007-08-01

3.  Production of podophyllotoxin from Podophyllum hexandrum: a potential natural product for clinically useful anticancer drugs.

Authors:  A Giri; M Lakshmi Narasu
Journal:  Cytotechnology       Date:  2000-10       Impact factor: 2.058

4.  Local Management of Anogenital Warts in Non-Immunocompromised Adults: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Antoine Bertolotti; Cyril Ferdynus; Brigitte Milpied; Nicolas Dupin; Laetitia Huiart; Christian Derancourt
Journal:  Dermatol Ther (Heidelb)       Date:  2020-02-06

5.  Local Management of Anogenital Warts in Non-immunocompromised Adults: A Systematic Review and Meta-analyses of Randomized Controlled Trials.

Authors:  Antoine Bertolotti; Brigitte Milpied; Sébastien Fouéré; Nicolas Dupin; André Cabié; Christian Derancourt
Journal:  Dermatol Ther (Heidelb)       Date:  2019-10-13

6.  Biochemical composition and antioxidant capacity of extracts from Podophyllum hexandrum rhizome.

Authors:  Mengfei Li; Lanlan Zhou; Delong Yang; Tiantian Li; Wei Li
Journal:  BMC Complement Altern Med       Date:  2012-12-22       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.